Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTB in Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
NCT01492673Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2011
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of bevacizumab in Ewing sarcoma, neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
Ewing sarcomaneuroblastoma
Beyond the preview
Go deeper on NCT01492673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01492673.